These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 20030427

  • 1. Besifloxacin ophthalmic suspension 0.6%.
    Carter NJ, Scott LJ.
    Drugs; 2010; 70(1):83-97. PubMed ID: 20030427
    [Abstract] [Full Text] [Related]

  • 2. Besifloxacin: a topical fluoroquinolone for the treatment of bacterial conjunctivitis.
    Chang MH, Fung HB.
    Clin Ther; 2010 Mar; 32(3):454-71. PubMed ID: 20399984
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
    McDonald MB, Protzko EE, Brunner LS, Morris TW, Haas W, Paterno MR, Comstock TL, Usner DW.
    Ophthalmology; 2009 Sep; 116(9):1615-1623.e1. PubMed ID: 19643483
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adolescents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials.
    Comstock TL, Paterno MR, Usner DW, Pichichero ME.
    Paediatr Drugs; 2010 Apr 01; 12(2):105-12. PubMed ID: 20218747
    [Abstract] [Full Text] [Related]

  • 5. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: A multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study.
    Karpecki P, Depaolis M, Hunter JA, White EM, Rigel L, Brunner LS, Usner DW, Paterno MR, Comstock TL.
    Clin Ther; 2009 Mar 01; 31(3):514-26. PubMed ID: 19393842
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and tolerability of besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study in adults and children.
    Silverstein BE, Allaire C, Bateman KM, Gearinger LS, Morris TW, Comstock TL.
    Clin Ther; 2011 Jan 01; 33(1):13-26. PubMed ID: 21397770
    [Abstract] [Full Text] [Related]

  • 7. Besifloxacin, a new ophthalmic fluoroquinolone for the treatment of bacterial conjunctivitis.
    Bertino JS, Zhang JZ.
    Expert Opin Pharmacother; 2009 Oct 01; 10(15):2545-54. PubMed ID: 19743941
    [Abstract] [Full Text] [Related]

  • 8. Besifloxacin ophthalmic suspension, 0.6%: a novel topical fluoroquinolone for bacterial conjunctivitis.
    O'Brien TP.
    Adv Ther; 2012 Jun 01; 29(6):473-90. PubMed ID: 22729919
    [Abstract] [Full Text] [Related]

  • 9. Besifloxacin ophthalmic suspension 0.6% administered twice daily for 3 days in the treatment of bacterial conjunctivitis in adults and children.
    DeLeon J, Silverstein BE, Allaire C, Gearinger LS, Bateman KM, Morris TW, Comstock TL.
    Clin Drug Investig; 2012 May 01; 32(5):303-17. PubMed ID: 22420526
    [Abstract] [Full Text] [Related]

  • 10. Besifloxacin ophthalmic suspension for bacterial conjunctivitis.
    Nafziger AN, Bertino JS.
    Drugs Today (Barc); 2009 Aug 01; 45(8):577-88. PubMed ID: 19927224
    [Abstract] [Full Text] [Related]

  • 11. Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates.
    Sanfilippo CM, Allaire CM, DeCory HH.
    Drugs R D; 2017 Mar 01; 17(1):167-175. PubMed ID: 28078599
    [Abstract] [Full Text] [Related]

  • 12. Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies.
    Comstock TL, Paterno MR, Decory HH, Usner DW.
    Clin Drug Investig; 2010 Mar 01; 30(10):675-85. PubMed ID: 20629472
    [Abstract] [Full Text] [Related]

  • 13. Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits.
    Proksch JW, Ward KW.
    J Ocul Pharmacol Ther; 2010 Oct 01; 26(5):449-58. PubMed ID: 20874668
    [Abstract] [Full Text] [Related]

  • 14. Clinical and Antibacterial Efficacy and Safety of Besifloxacin Ophthalmic Suspension Compared With Moxifloxacin Ophthalmic Solution.
    Garg P, Mathur U, Sony P, Tandon R, Morris TW, Comstock TL.
    Asia Pac J Ophthalmol (Phila); 2015 Oct 01; 4(3):140-5. PubMed ID: 26065499
    [Abstract] [Full Text] [Related]

  • 15. The role of besifloxacin in the treatment of bacterial conjunctivitis.
    Mahvan TD, Hornecker JR, Buckley WA, Clark S.
    Ann Pharmacother; 2014 May 01; 48(5):616-25. PubMed ID: 24566460
    [Abstract] [Full Text] [Related]

  • 16. Characterization of baseline polybacterial versus monobacterial infections in three randomized controlled bacterial conjunctivitis trials and microbial outcomes with besifloxacin ophthalmic suspension 0.6.
    DeCory HH, Sanfilippo CM, Proskin HM, Blondeau JM.
    PLoS One; 2020 May 01; 15(8):e0237603. PubMed ID: 32841261
    [Abstract] [Full Text] [Related]

  • 17. Rate of bacterial eradication by ophthalmic solutions of fourth-generation fluoroquinolones.
    Callegan MC, Novosad BD, Ramadan RT, Wiskur B, Moyer AL.
    Adv Ther; 2009 Apr 01; 26(4):447-54. PubMed ID: 19381523
    [Abstract] [Full Text] [Related]

  • 18. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis.
    Tepedino ME, Heller WH, Usner DW, Brunner LS, Morris TW, Haas W, Paterno MR, Comstock TL.
    Curr Med Res Opin; 2009 May 01; 25(5):1159-69. PubMed ID: 19323612
    [Abstract] [Full Text] [Related]

  • 19. The safety of besifloxacin ophthalmic suspension 0.6 % used three times daily for 7 days in the treatment of bacterial conjunctivitis.
    Malhotra R, Ackerman S, Gearinger LS, Morris TW, Allaire C.
    Drugs R D; 2013 Dec 01; 13(4):243-52. PubMed ID: 24142473
    [Abstract] [Full Text] [Related]

  • 20. Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli.
    Cambau E, Matrat S, Pan XS, Roth Dit Bettoni R, Corbel C, Aubry A, Lascols C, Driot JY, Fisher LM.
    J Antimicrob Chemother; 2009 Mar 01; 63(3):443-50. PubMed ID: 19147516
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.